

Reference number
1977-H

SPECIALTY QUANTITY LIMIT PROGRAM

ORENCIA (abatacept)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit	Exception Limit
Orencia (abatacept) subcutaneous injection: 50 mg per 0.4 ml syringe	<ul style="list-style-type: none"> • RA and PsA (adult): 125 mg once weekly • PJIA, weight 10 kg to < 25 kg: 50 mg once weekly • PJIA, weight 25 kg to < 50 kg: 87.5 mg once weekly • PJIA, weight ≥ 50 kg: 125 mg once weekly 	4 syringes per 28 days	N/A
Orencia (abatacept) subcutaneous injection: 87.5 mg per 0.7 ml syringe		4 syringes per 28 days	N/A
Orencia (abatacept) subcutaneous injection: 125 mg per ml syringe		4 syringes per 28 days	N/A
Orencia (abatacept) intravenous: 250 mg single-use vial	<ul style="list-style-type: none"> • RA and PsA (adult) at week 0, 2, and 4 then every 4 weeks <ul style="list-style-type: none"> ○ Weight less than 60 kg: 500 mg ○ Weight 60 kg to 100 kg: 750 mg ○ Weight more than 100 kg: 1000 mg • PJIA <ul style="list-style-type: none"> ○ Weight less than 75 kg: 10 mg per kg ○ Weight 75 kg or more: following the RA/PsA dosing above 	4 vials every 4 weeks	12 vials per 29 days*

Abbreviations: RA = rheumatoid arthritis; PsA = psoriatic arthritis; PJIA = polyarticular juvenile idiopathic arthritis

*Loading doses are addressed by the post-limit quantity exceptions criteria.

III. REFERENCE

- Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; June 2017.